Scarica l'app Stockscreener
23.24
1.81%
-0.52
Precedente Chiudi:
$23.76
Aprire:
$24.03
Volume 24 ore:
396.84K
Relative Volume:
0.24
Capitalizzazione di mercato:
$1.48B
Reddito:
-
Utile/perdita netta:
$-107.85M
Rapporto P/E:
-10.52
EPS:
-2.21
Flusso di cassa netto:
$-106.82M
1 W Prestazione:
-2.06%
1M Prestazione:
+11.52%
6M Prestazione:
-30.09%
1 anno Prestazione:
-33.00%
Intervallo 1D:
$23.03
$24.03
Intervallo di 1 settimana:
$22.91
$24.03
Portata 52W:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Confronta VERA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
23.23 | 1.55B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.44 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.49 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.53 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
293.85 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
What drives Vera Therapeutics Inc. stock priceFree Stock Selection - Jammu Links News
What analysts say about Vera Therapeutics Inc. stockExceptional risk-adjusted gains - Jammu Links News
how vera therapeutics inc. stock performs during market volatilityFree Deep Market Trend Analysis - Newser
What makes Vera Therapeutics Inc. stock price move sharplyFree Stock Market Forums - Newser
Why Vera Therapeutics Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
How Vera Therapeutics Inc. stock performs during market volatilityFree Deep Market Trend Analysis - Newser
Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy - MSN
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans - MSN
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Expands Team with 200K+ Shares in Stock Options and RSUs for New Hires - Stock Titan
How to Take Advantage of moves in (VERA) - news.stocktradersdaily.com
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Insider Buying Activity - Defense World
Vera Therapeutics director Enright buys shares worth $5.2m By Investing.com - Investing.com UK
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan
H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada
Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World
California State Teachers Retirement System Acquires 6,749 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down – Should You Sell? - Defense World
Otsuka Jumps Most in Five Years on Successful Kidney Drug Trial - Bloomberg.com
Biotech Stocks To Watch Today – June 6th - Defense World
Biotech Stock Vera Is Slumping After Monster Gain - MSN
Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com
Vera Therapeutics (VERA) Drops 32% After Trial Results Disappoin - GuruFocus
Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News
Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Nigeria
Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia
Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha
Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Research Analysts Offer Predictions for VERA FY2027 Earnings - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vera Therapeutics Inc Azioni (VERA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
0.86%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):